COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
DelveInsight’s “Von Willebrand disease (VWD) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Von Willebrand disease (VWD), historical and forecasted epidemiology as well as the Von Willebrand disease (VWD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Von Willebrand disease (VWD) market report provides current treatment practices, emerging drugs, Von Willebrand disease (VWD) market share of the individual therapies, current and forecasted Von Willebrand disease (VWD) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Von Willebrand disease (VWD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Von Willebrand disease (VWD) market.
Some of the key facts of the Von Willebrand Disease Market:
●VWD is the most common bleeding disorder, found in up to 1% of the U.S. population. This means that 3.2 million (or about 1 in every 100) people in the United States have the disease.
●VWD occurs among men and women equally, women are more likely to notice the symptoms because of heavy or abnormal bleeding during their menstrual periods and after childbirth.
Got queries? Click here to know more about the Von Willebrand Disease Market Landscape
Von Willebrand Disease Overview
A bleeding disorder caused by low levels of clotting protein in the blood. Von Willebrand disease is often inherited, but in rare cases, it may develop later in life. Symptoms may include recurrent and prolonged nosebleeds, bleeding from the gums, increased menstrual flow and excessive bleeding from a cut. Treatment focuses on stopping or preventing bleeding episodes, typically by using medication.The three forms of VWD are hereditary, acquired, and pseudo or platelet type. The three types of hereditary VWD are VWD type 1, VWD type 2, and VWD type 3. Type 2 contains various subtypes. Platelet type VWD is also an inherited condition.asic tests performed in any patient with bleeding problems are a complete blood count-CBC (especially platelet counts), activated partial thromboplastin time-APTT, prothrombin time with International Normalized Ratio-PTINR, thrombin time-TT, and fibrinogen level. Patients with abnormal tests typically undergo further testing for hemophilias. Other coagulation factor assays may be performed depending on the results of a coagulation screen. Patients with von Willebrand disease typically display a normal prothrombin time and a variable prolongation of partial thromboplastin tim
Von Willebrand Disease Epidemiology Insights:
●Von Willebrand disease is estimated to affect approximately 1% of the unselected population, but clinically significant disease prevalence is estimated to be about 125 per million, with severe disease affecting up to five per million.
●There is an equal distribution between males and females. Acquired von Willebrand disease prevalence is unknown but may represent 1% to 5% of all von Willebrand disease. Its prevalence is higher in certain groups. For example, it has been reported in up to 20% of malignancies and up to 100% of certain high flow states such as extracorporeal membrane oxygenation (ECMO) and metallic cardiac valves.
Von Willebrand Disease Epidemiology Segmentation
●Total Von Willebrand Disease patient segmentation
●Total Von Willebrand Disease risk factors
●Total Von Willebrand Disease diagnostic cases
●Total Von Willebrand Disease treatment cases
●Total Von Willebrand Disease growth-related factors observed in patients
Von Willebrand Disease Market Outlook
The Von Willebrand disease (VWD) market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Von Willebrand disease (VWD) market trends by analyzing the impact of current Von Willebrand disease (VWD) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Von Willebrand disease (VWD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Von Willebrand disease (VWD) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Von Willebrand disease (VWD) market in 7MM is expected to change in the study period 2019-2032 significantly.
Learn more by requesting for sample @ Von Willebrand Disease Market Trends
Von Willebrand Disease Key Companies
●CSL Behring
●Grifols
●Takeda
●Octapharma
●Sanofi
●And many others
Von Willebrand Disease Therapies
●Efanesoctocog alfa (BIVV001)
●ARC1779
●Emicizumab
●Desmopressin
●Wilate
●And many others
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Von Willebrand Disease
4. Disease Background and Overview
5. Epidemiology and patient population
6. The United States
7. EU 5
8. Von Willebrand Disease Emerging Therapies
9. Von Willebrand Disease Market Outlook
10. Market Access and Reimbursement of Therapies
11. Market Drivers
12. Market Barriers
13. Appendix
14. Von Willebrand Disease Report Methodology
15.DelveInsight Capabilities
16. Disclaimer
Click here to read more about Von Willebrand Disease Market Trends
Related Reports
Von Willebrand Disease Pipeline Insights, 2022
Von Willebrand Disease Pipeline Insights, 2022″ report by DelveInsight outlays comprehensive insights of the present clinical development scenario and growth prospects across the Von Willebrand Disease market. A detailed picture of the Von Willebrand Disease pipeline landscape is provided, which includes the disease overview and Von Willebrand Disease treatment guidelines. The assessment part of the report embraces in-depth Von Willebrand Disease commercial assessment and clinical assessment of the Von Willebrand Disease pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Von Willebrand Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Trending Reports
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com